title: Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly.
abstract: Consensus statement of the Polish Society for Endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then 30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets: biochemical improvement, reduced risk of disease's complications, perioperative risk reduction, inhibition of tumor growth). The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease's complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow objective evaluation of long-term efficacy of the treatment.
authors.affiliation: Department of Endocrinology, Diabetology and Isotope Therapy, Medical University Wrocław, Poland. bolan@endo.am.wroc.pl
authors.forename: Marek
authors.initials: M
authors.lastname: Bolanowski
authors.forename: Ewa
authors.initials: E
authors.lastname: Bar-Andziak
authors.forename: Beata
authors.initials: B
authors.lastname: Kos-Kudła
authors.forename: Barbara
authors.initials: B
authors.lastname: Krzyzanowska-Swiniarska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Lewiński
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Łomna-Bogdanov
authors.forename: Andrzej
authors.initials: A
authors.lastname: Milewicz
authors.forename: Jerzy
authors.initials: J
authors.lastname: Sowiński
authors.forename: Wojciech
authors.initials: W
authors.lastname: Zgliczyński
mesh_terms: D006801:Humans; D000172:Acromegaly / Q000097:blood / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D013006:Growth Hormone / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011044:Poland; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D013006:Growth Hormone; D007334:Insulin-Like Growth Factor I; C060347:lanreotide; D015282:Octreotide; D010456:Peptides, Cyclic; D013004:Somatostatin